Wells Fargo & Co (NYSE:WFC) posted Q3 earnings per share in line with analysts' consensus while revenue came in slightly above the Street view. Wells Fargo & Co (NYSE:WFC) trades within in a 52-week range of $40.30 to $53.80. Investors were disappointed the EPS didn't top the Street's forecast. Net income applicable to common stock was $5.41 billion, or $1.02 per diluted share, up from $5.32 billion, or $0.99 per diluted share, a year earlier. Analysts polled by Capital IQ had predicted $1.02. Revenue--or net interest income plus noninterest income--rose to $21.21 billion, from $20.47 billion a year earlier. Analysts were targeting $21.06 billion."Loan and deposit growth was strong and diversified across both commercial and consumer businesses," said Chairman and CEO John Stumpf. "Capital levels increased even as we returned more capital to shareholders through higher dividends and share repurchases from a year ago. We continue to see signs of a steadily improving economy, and I remain optimistic about the opportunities ahead for Wells Fargo."Rentrak Corporation (NASDAQ:RENT) a media measurement and information company, said it signed an agreement with Twenty-First Century Fox's (FOX, FOXA) Fox Networks Group to expand its existing relationship to include linear TV ratings measurement and single source consumer data reporting. Fox Networks Group's FOX Broadcasting, FX Networks and National Geographic channels will access Rentrak's complete TV ratings measurement insights to help transform the valuation and monetization of its media inventory. Rentrak Corporation (NASDAQ:RENT) shares are trading with a 52-week range of $34.01-$75.39.DARA Biosciences Inc (NASDAQ:DARA), the biopharmaceutical company said its product Gelclair became the number one oral gel barrier prescription product in the U.S. retail market. Gelclair is indicated for the management of oral mucositis. According to data provided by Symphony Health Solutions, Gelclair had more prescriptions filled in the U.S. retail sector than any other prescription oral gel barrier agent. Beginning in June, the product became the most frequently prescribed retail oral gel barrier agent and maintained its leadership through August. Gelclair is the only oral gel barrier product to demonstrate continued month over month retail prescription growth since February 2014, according to the latest data through August. DARA Biosciences Inc (NASDAQ:DARA) shares are moving within a 52-week range of $0.79-$4.40. The shares touched a new all-time low of $0.79 on Monday before closing at $0.82.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
